Literature DB >> 27220728

Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.

Jin Ye1, Laisheng Li2, Pinning Feng2, Jianxin Wan2, Jingjia Li1.   

Abstract

Laryngeal carcinoma is one of the most common head and neck cancers. MicroRNAs are a class of small non-coding RNAs 18-25 nucleotides in length that post-transcriptionally regulate gene expression and have a pivotal role in many biological processes including cancer development. In this study, we investigated the role of miR-34a in laryngeal carcinoma and confirmed the regulation of cyclin D1 (CCND1) by miR-34a. We examined miR-34a expression levels in 71 laryngeal carcinoma patient specimens by quantitative reverse transcription-PCR, and analyzed the clinicopathological significance of the obtained data. Then, functional assays were performed to investigate the potential effects of miR-34a on cancer cell proliferation and migration. In addition, western blotting, luciferase reporter assay and several algorithms were conducted to confirm that CCND1 is directly regulated by miR-34a. We demonstrated that the miR-34a expression level was significantly downregulated in laryngeal carcinoma clinical specimens compared with that observed in their paired adjacent normal tissues. Additionally, miR-34a expression was also inversely correlated with lymph node metastasis and clinical stage. Functional assays showed that ectopic expression of miR-34a inhibited cell proliferation and migration in laryngeal carcinoma cells. Bioinformatic analysis identified CCND1 as a potential target of miR-34a. Moreover, we confirmed that miR-34a inhibited the expression of CCND1 by directly binding to its 3'-untranslated region. Silencing of CCND1 induced effects similar to those of miR-34a ectopic expression, and in laryngeal carcinoma tissues, miR-34a and CCND1 were inversely correlated. Our data suggest that tumor suppressor miR-34a could serve as a new potential diagnostic marker and that ectopic expression of miR-34a may be used as a therapeutic target for laryngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27220728     DOI: 10.3892/or.2016.4823

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells.

Authors:  Hasan Onur Caglar; Cigir Biray Avci
Journal:  Mol Biol Rep       Date:  2020-02-28       Impact factor: 2.316

2.  Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.

Authors:  Kuang-Hueih Chen; Asish Dasgupta; Jianhui Lin; François Potus; Sébastien Bonnet; James Iremonger; Jennifer Fu; Jeffrey Mewburn; Danchen Wu; Kimberly Dunham-Snary; Anne L Theilmann; Zhi-Cheng Jing; Charles Hindmarch; Mark L Ormiston; Allan Lawrie; Stephen L Archer
Journal:  Circulation       Date:  2018-02-05       Impact factor: 29.690

3.  miR-34a inhibits pancreatic cancer progression through Snail1-mediated epithelial-mesenchymal transition and the Notch signaling pathway.

Authors:  Yan Tang; Yong Tang; Ying-Sheng Cheng
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

Review 4.  Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.

Authors:  Takashi Takeuchi; Hiromichi Kawasaki; Amalia Luce; Alessia Maria Cossu; Gabriella Misso; Marianna Scrima; Marco Bocchetti; Filippo Ricciardiello; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 5.  The Role of microRNAs in Multidrug Resistance of Glioblastoma.

Authors:  Parvaneh Mahinfar; Behnaz Mansoori; Davoud Rostamzadeh; Behzad Baradaran; William C Cho; Behzad Mansoori
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 6.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 7.  Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in laryngeal squamous cell cancer.

Authors:  Yan Huang; Min Gu; Yiting Tang; Zhiqiang Sun; Judong Luo; Zhe Li
Journal:  Cancer Cell Int       Date:  2021-06-22       Impact factor: 5.722

8.  Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis.

Authors:  Guangchao Duan; Chuanlin Zhang; Changke Xu; Chao Xu; Lei Zhang; Yan Zhang
Journal:  Int J Oncol       Date:  2018-10-19       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.